BREAKING: Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks
To Profit From This News, Contact us today, and let us demonstrate how we can elevate your portfolio to new levels